Current problems in cancer. Case reports最新文献_第2页

Review of outcomes in a veteran treated with lurbinectedin long-term for extensive-stage small cell lung cancer: A case report

IF 0.2

Current problems in cancer. Case reports Pub Date : 2025-01-10 DOI: 10.1016/j.cpccr.2025.100350

Jana Sawyer , Megan Banaszynski , Brian Do , Jesse Cobell

{"title":"Review of outcomes in a veteran treated with lurbinectedin long-term for extensive-stage small cell lung cancer: A case report","authors":"Jana Sawyer , Megan Banaszynski , Brian Do , Jesse Cobell","doi":"10.1016/j.cpccr.2025.100350","DOIUrl":"10.1016/j.cpccr.2025.100350","url":null,"abstract":"<div><div>Small cell lung cancer comprises approximately 10% to 15% of all lung cancers but is associated with a high proliferation rate and poor prognosis. Treatment options for patients with small cell lung cancer have been limited and offer modest clinical benefit. Lurbinectedin, an approved treatment by the United States Food and Drug Administration for metastatic small cell lung cancer in adults with disease progression during or after platinum-based chemotherapy, was shown to have antitumor activity and a favorable safety profile in a phase II trial. Here, we present a case report of a patient who was treated with lurbinectedin for approximately 2 years and maintained stable disease while receiving a reduced dose. The patient developed grade 3 anemia which resolved following a dose reduction of lurbinectedin, allowing for mitigation of toxicity while maintaining the clinical efficacy of the drug. Clinicians who treat patients with small cell lung cancer should be aware of this extended use of lurbinectedin in a patient who relapsed following first-line treatment and maintained stable disease on a reduced dose for almost 2 years.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100350"},"PeriodicalIF":0.2,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

mTOR inhibition with sirolimus is associated with a durable response in HIV associated multifocal Epstein-Barr Virus associated smooth muscle Tumour (EBV-SMT) and mini review of novel therapeutic options

IF 0.2

Current problems in cancer. Case reports Pub Date : 2025-01-09 DOI: 10.1016/j.cpccr.2024.100344

John Kh Ang , Daniel Ry Yap , Khoon Leong Chuah , Jens Samol

{"title":"mTOR inhibition with sirolimus is associated with a durable response in HIV associated multifocal Epstein-Barr Virus associated smooth muscle Tumour (EBV-SMT) and mini review of novel therapeutic options","authors":"John Kh Ang , Daniel Ry Yap , Khoon Leong Chuah , Jens Samol","doi":"10.1016/j.cpccr.2024.100344","DOIUrl":"10.1016/j.cpccr.2024.100344","url":null,"abstract":"<div><div>Epstein-Barr Virus associated smooth muscle tumour (EBV-SMT) is a rare tumour with an estimated prevalence of <2 cases per million. It develops in patients who are immunocompromised and in whom the risk of EBV reactivation causing tumorigenesis is high. Examples of immunocompromised states include patients infected with human immunodeficiency virus (HIV), patients on iatrogenic immunosuppression following transplantation and patients with primary/congenital immunodeficiency. Although the association between EBV and development of EBV-SMT is well established, the underlying pathophysiology for this association is unclear.</div><div>We present a case of a patient with HIV related EBV-SMT who has been on treatment with sirolimus for >5 years with disease continuing to remain controlled, clearly demonstrating the durable activity of sirolimus in the management of EBV-SMT. We scrutinized the literature pertaining to novel therapeutics which have been used for the management of EBV-SMTs and set it into context with other EBV associated neoplasms.</div><div>To our knowledge, this is the first case report of a patient treated with sirolimus and we recommend that mTOR inhibition with sirolimus be considered as a first therapeutic option together with HAART in patients with HIV associated EBV-SMTs.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100344"},"PeriodicalIF":0.2,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early onset venous and arterial thrombosis when combining Osimertinib and Amivantamab in NSCLC: Instructive cases and literature review

IF 0.2

Current problems in cancer. Case reports Pub Date : 2025-01-01 DOI: 10.1016/j.cpccr.2024.100348

Alexander S Watson, Tejas Patil, Erin L Schenk, D Ross Camidge

{"title":"Early onset venous and arterial thrombosis when combining Osimertinib and Amivantamab in NSCLC: Instructive cases and literature review","authors":"Alexander S Watson, Tejas Patil, Erin L Schenk, D Ross Camidge","doi":"10.1016/j.cpccr.2024.100348","DOIUrl":"10.1016/j.cpccr.2024.100348","url":null,"abstract":"<div><div>The bispecific antibody amivantamab has evidence in multiple combinations and indications for treating advanced Epidermal Growth Factor Receptor (EGFR) mutated NSCLC, including a recently approved first line combination with the third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib. Thrombotic complications have been reported at elevated rates for amivantamab-lazertinib combinations in clinical trials. While awaiting lazertinib approval, the previously established third-generation EGFR TKI osimertinib has been utilized by some clinicians in combinations with amivantamab, and this substitution will likely continue to be used in certain clinical contexts. Whether osimertinib-amivantamab combinations also carry thrombotic risk has not been described. Here, we outline three patient cases from our institution where osimertinib-amivantamab combinations were employed, highlighting early development of venous thromboembolism, arterial thrombosis, and use of anticoagulation prophylaxis. We review these cases in the context of the existing literature exploring thrombotic complications with amivantamab combinations. Clinicians should be aware of, discuss with patients, and take steps to mitigate, thrombotic risk with amivantamab-EGFR TKI combination therapy.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100348"},"PeriodicalIF":0.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transformation of PSMA-avid to FDG-avid disease in metastatic castration-resistant prostate cancer in the setting of biochemical response with LU177-PSMA-617

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-12-31 DOI: 10.1016/j.cpccr.2024.100347

A Sidhu , P Singh

引用次数: 0

A case of opsoclonus-myoclonus syndrome associated with breast cancer

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-12-19 DOI: 10.1016/j.cpccr.2024.100346

Sebastian Mohar , Naomi Fujioka , Todd Tuttle , Bruce Trautman , Emilian Racila , Jianling Yuan , Sean J. Pittock , David A. Potter

引用次数: 0

Olanzapine-induced hypertriglyceridemia in cancer care: A silent metabolic risk

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-12-18 DOI: 10.1016/j.cpccr.2024.100345

Bilal Kazi , Imaan Rumani , Marzooka Nazim Chishti Kazi , Prashant Manohar Gaikwad

引用次数: 0

Pleural mesothelioma: Long-term progression-free survival with Tumor Treating Fields (TTFields) therapy case reports

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-11-30 DOI: 10.1016/j.cpccr.2024.100342

Giovanni Luca Ceresoli , Laura Mannarino , Lara Paracchini , Federica Grosso

引用次数: 0

Excellent response of cetuximab plus chemotherapy after pembrolizumab monotherapy in metastatic hypopharyngeal cancer: A case report

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-11-28 DOI: 10.1016/j.cpccr.2024.100338

Anh Tuan Pham , Thang Huu Nguyen , Thai Hong Le , Toan Khanh Phan , Anh Phuong Nguyen , Ngoc Minh Le , Thao Thu Vu

{"title":"Excellent response of cetuximab plus chemotherapy after pembrolizumab monotherapy in metastatic hypopharyngeal cancer: A case report","authors":"Anh Tuan Pham , Thang Huu Nguyen , Thai Hong Le , Toan Khanh Phan , Anh Phuong Nguyen , Ngoc Minh Le , Thao Thu Vu","doi":"10.1016/j.cpccr.2024.100338","DOIUrl":"10.1016/j.cpccr.2024.100338","url":null,"abstract":"<div><div>Patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) typically have an unfavorable prognosis, with a median survival of only 6 to 15 months in most studies. In cases other than local relapse or oligometastases, systemic therapy plays the dominant role. The choice of regimen is influenced by multiple clinical factors, including patient comorbidities, performance status, previous therapy, and pathologic features. We present a case of PD-L1 (programmed death-ligand 1)-negative metastatic hypopharyngeal cancer successfully treated with pembrolizumab monotherapy, followed by cetuximab combined with chemotherapy. Remarkably, the patient currently remains in good health, with no signs of disease on imaging at 35 months after diagnosis. We emphasized the importance of a well-devised treatment strategy, as well as the significant synergistic effects of the sequence in which the cetuximab-based regimen follows immune checkpoint inhibitors.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100338"},"PeriodicalIF":0.2,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HER2-positive breast cancer in patients with BRCA1/2 pathogenic variants: Case series and literature review BRCA1/2致病变异患者的her2阳性乳腺癌：病例系列和文献综述

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-11-25 DOI: 10.1016/j.cpccr.2024.100335

Pujita Munnangi , Polly Ann Niravath , Jenny C Chang , Kai Sun

{"title":"HER2-positive breast cancer in patients with BRCA1/2 pathogenic variants: Case series and literature review","authors":"Pujita Munnangi , Polly Ann Niravath , Jenny C Chang , Kai Sun","doi":"10.1016/j.cpccr.2024.100335","DOIUrl":"10.1016/j.cpccr.2024.100335","url":null,"abstract":"<div><h3>Research purpose</h3><div>HER2-positive breast cancers are uncommonly reported in patients with <em>BRCA1/2</em> pathogenic variants. The purpose of this case series is to describe three patients with <em>BRCA1/2</em> pathogenic variants who developed HER2-positive breast cancers and their treatment courses along with that of a patient from a previously published case report, and describe existing literature exploring associations between HER2<em>-</em>positive breast cancers and germline variants.</div></div><div><h3>Key findings</h3><div>HER2-positive breast cancer is uncommon in patients with <em>BRCA1/2</em> pathogenic variants. The patients in our case series had hormone receptor positive and HER2-positive breast cancers. HER2 FISH was commonly utilized for the confirmation of HER2 status in our case series. All patients responded well to HER-2 directed therapies.</div></div><div><h3>Conclusions & clinical implications</h3><div>While the interactions between <em>BRCA1/2</em> pathogenic variants and the HER2 pathway are unclear, our case series and existing literature suggest that HER2-positive breast cancer occurrence is mainly HER2 oncogenic pathway driven. But the interplay between the DNA repair pathway and the HER2 oncogenic pathway could impact HER2 gene expression and play a potentially important role in treatment resistance and therapy options. Combining olaparib and trastuzumab could be considered for off-label use in patients with <em>BRCA 1/2</em> mutations with HER2-positive breast cancer who failed HER2-targeted therapy.</div></div><div><h3>Limitations</h3><div>This study is limited by small sample size (<em>n</em> = 4). Since it is a retrospective study, it is also limited by selection bias, lack of control group for comparison purposes, and potential influence of confounding variables.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100335"},"PeriodicalIF":0.2,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Restoring sensitivity to daratumumab with all-transretinoic acid in a patient with daratumumab-refractory multiple myeloma: A case report and review of the literature 全经维甲酸恢复达拉单抗难治性多发性骨髓瘤患者对达拉单抗的敏感性：一个病例报告和文献回顾

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-11-23 DOI: 10.1016/j.cpccr.2024.100336

Noa Biran , David H. Vesole , Harsh Parmar , Pooja Phull , Susan Kumka , Kimberly Doucette , Joshua Zenreich , Bianca DeAgresta , Alexandra Della Pia , Lisa Biamonte , Martha Campanaro , Trina McClendon , Samanta BaboolallAracena , Palka Anand , Adolfo Aleman , Monique Pace , Genevieve Breeze , Kristin Ivanovski , Marie Layton , David S. Siegel

引用次数: 0